CN114668771B - Preparation method and application of ferritin nanoparticles loaded with adriamycin and ursolic acid together - Google Patents
Preparation method and application of ferritin nanoparticles loaded with adriamycin and ursolic acid together Download PDFInfo
- Publication number
- CN114668771B CN114668771B CN202210273421.6A CN202210273421A CN114668771B CN 114668771 B CN114668771 B CN 114668771B CN 202210273421 A CN202210273421 A CN 202210273421A CN 114668771 B CN114668771 B CN 114668771B
- Authority
- CN
- China
- Prior art keywords
- ferritin
- loaded
- adriamycin
- ursolic acid
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a preparation method and application of a ferritin drug-loaded nanoparticle jointly loaded with two drugs, the nanoparticle effectively delivers the two drugs by targeting on a tumor cell transferrin receptor 1 (TfR 1), compared with the delivery of a single drug, the method can further enhance the anti-tumor curative effect and reduce the generation of drug resistance, and the ferritin drug-loaded nanoparticle loads the two drugs together by ferritin, has simple steps, keeps the original structure of the ferritin complete and has good application prospect.
Description
Technical Field
The invention belongs to the technical field of anti-tumor, and particularly relates to a preparation method and application of a ferritin nanoparticle co-loaded with adriamycin and ursolic acid.
Background
Cancer is a serious threat to human life and health, and is the second leading disease of death in the human body worldwide. Although chemotherapy is one of the most effective methods for treating cancer clinically, chemotherapy drugs often kill tumor cells and human normal cells. Therefore, chemotherapy may produce strong toxic side effects that may lead to adverse reactions. In order to cope with the above problems, nano-drug delivery systems such as liposomes, polymer micelles, lipid-based nano-carriers, inorganic nano-carriers, and the like have been developed and utilized. In addition, the protein nanoparticles have the characteristics of good biocompatibility and the like, so that the protein nanoparticles become a very potential drug delivery system.
Human heavy chain ferritin (HFtn) is a spherical cage-shaped protein nanomaterial with an outer diameter of 12nm and an inner diameter of 8 nm. Ferritin as a nano carrier has the characteristics of low immunogenicity, biodegradability, specific targeting of TfR1 and the like. Therefore, ferritin plays an important role in the field of cancer therapy. The ferritin loaded with a single drug has undesirable antitumor effect and can suffer from drug resistance and other problems. Therefore, in order to improve the anti-tumor effect and reduce the toxic and side effects of the drugs, the ferritin inner cavity is used for simultaneously loading the two drugs, and the synergistic effect of the two drugs is utilized to enhance the anti-tumor effect, so that the method is a promising strategy.
Disclosure of Invention
This section is for the purpose of summarizing some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. In this section, as well as in the abstract and the title of the invention of this application, simplifications or omissions may be made to avoid obscuring the purpose of the section, the abstract and the title, and such simplifications or omissions are not intended to limit the scope of the invention.
In order to improve the therapeutic effect and reduce the generation of drug resistance, most cancer treatments in clinic use anticancer drugs with different mechanisms in combination. The invention provides a preparation method of a ferritin drug-loaded nanoparticle jointly loaded with two drugs, the ferritin nanoparticle effectively delivers the two drugs through targeting of a tumor cell transferrin receptor 1 (TfR 1), compared with the delivery of a single drug, the method can further enhance the anti-tumor curative effect and reduce the generation of drug resistance, and has good application prospect.
The inventor has tried various methods to load the drug required for the experiment, and there are three main methods for loading ferritin with the drug: pH method, temperature method, and urea method. Compared with the pH method, the temperature method can greatly reduce the loss of ferritin and improve the loading capacity, and the pH method only has a very small amount of drugs to be loaded; compared with the low-concentration urea treatment, the temperature method can load two medicines simultaneously and further enhance the quantity of the loaded medicines, and the pH method is not suitable for further research because only a few medicines are loaded and the protein loss is too large, while the low-concentration urea method can only load one medicine but cannot load two medicines of adriamycin and ursolic acid simultaneously. Therefore, the invention mainly provides a preparation method and application of the ferritin nanoparticles carrying both adriamycin and ursolic acid by a temperature method.
Therefore, the invention aims to provide a preparation method and application of a ferritin nanoparticle loaded with adriamycin and ursolic acid together.
In order to solve the above technical problems, according to one aspect of the present invention, the present invention provides the following technical solutions: a preparation method of ferritin nanoparticles with co-loaded adriamycin and ursolic acid comprises,
the ferritin nanoparticles are loaded with two drugs, namely hydrophilic drug and hydrophobic drug.
As a preferable scheme of the preparation method of the ferritin nanoparticle co-loaded with adriamycin and ursolic acid, the invention also comprises the following steps,
adding the medicines into the ferritin solution respectively, incubating, centrifuging, separating supernatant, and dialyzing in PBS; and (4) carrying out centrifugal filtration to obtain the co-drug-loaded nanoparticle.
As a preferred scheme of the preparation method of the ferritin nanoparticle co-loaded with adriamycin and ursolic acid, the method comprises the following steps: the medicine is hydrophilic adriamycin and hydrophobic ursolic acid.
As a preferred scheme of the preparation method of the ferritin nanoparticle co-loaded with adriamycin and ursolic acid, the method comprises the following steps: the adriamycin is PBS solution of adriamycin; the ursolic acid is ethanol solution of ursolic acid.
As a preferred scheme of the preparation method of the ferritin nanoparticle co-loaded with adriamycin and ursolic acid, the method comprises the following steps: the ferritin solution is Tris-HCl solution of human heavy chain ferritin, the concentration is 20mM, and the pH is =8.0.
As a preferable scheme of the preparation method of the ferritin nanoparticle co-loaded with adriamycin and ursolic acid, the invention comprises the following steps: the molar ratio of the adriamycin to the ferritin in the co-loaded drug nanoparticles is 50-300: 1, the molar ratio of the ursolic acid to the ferritin is 450:1.
as a preferable scheme of the preparation method of the ferritin nanoparticle co-loaded with adriamycin and ursolic acid, the invention comprises the following steps: the incubation is carried out in a constant temperature water bath kettle at 60 ℃ for 4-5 hours.
As a preferable scheme of the preparation method of the ferritin nanoparticle co-loaded with adriamycin and ursolic acid, the invention comprises the following steps: and centrifuging after incubation at the rotating speed of 12000rpm for 10-15 min. As a preferred scheme of the preparation method of the ferritin nanoparticle co-loaded with adriamycin and ursolic acid, the method comprises the following steps: dialyzing in PBS for 24-48 h at 4 ℃ and changing PBS every 6 hours; the centrifugal filtration is carried out, the centrifugal condition is 5000 Xg, and the centrifugal time is 5-10 min.
The co-drug-loaded nanoparticle prepared by the preparation method of the ferritin nanoparticle co-loaded with adriamycin and ursolic acid is applied to delivery of antitumor drugs.
The invention has the beneficial effects that:
the invention provides a preparation method and application of a ferritin drug-loaded nanoparticle carrying two drugs together, the nanoparticle effectively delivers the two drugs by targeting on a tumor cell transferrin receptor 1 (TfR 1), compared with delivering a single drug, the method can further enhance the anti-tumor curative effect and reduce the generation of drug resistance, and the invention loads the two drugs together through ferritin, has simple steps, does not change the original structure of ferritin, and can greatly reduce the loss of ferritin and improve the loading capacity compared with a pH method; compared with low-concentration urea treatment, the method can load two drugs simultaneously, can further enhance the quantity of the loaded drugs, and has good application prospect.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without inventive exercise. Wherein:
FIG. 1 is a schematic diagram showing the loading of the medicines Doxorubicin (DOX) and Ursolic Acid (UA) by ferritin in example 1 and example 2; wherein (A) adding low concentration urea to expand the channel on the protein shell, allowing the drug to enter the protein cavity, dialyzing to remove urea and free drug, and contracting the pore channel to fix the drug in the cavity; (B) Adding DOX and UA into protein solution, incubating at 60 deg.C for 4 hr, enlarging protein channel, introducing medicine into lumen, and dialyzing to remove free medicine.
FIG. 2 is a characterization of drug-loaded ferritin and ferritin nanoparticles in example 1; wherein, the recombinant protein (A) is expressed in colon bacillus, and an expected gel band is obtained by nickel column and SEC purification, which indicates that the required protein is successfully purified; (B) low concentration urea treatment and heat treatment of the prepared samples; (C) The circular dichroism chromatogram of four kinds of nano particles of HFtn, HFtn-DOX/UA, HFtn-DOX and HFtn-UA shows that the prepared nano particles have obvious characteristic absorption peaks near 208nm and 222 nm. The encapsulation of DOX and UA drugs in the ferritin lumen has no influence on the ferritin secondary structure and is still alpha-helix; (D) SEC polymerization state analysis of the four kinds of nanoparticles can obtain that the prepared nanoparticles are still 24-mer, which proves that the drug is encapsulated in the protein cage, and the polymerization state of the protein carrier is not influenced by heat treatment; (E) According to transmission electron microscope images before and after drug encapsulation, the four types of nano particles are still in a cage-shaped structure with uniform particle size, which indicates that the loading of DOX and UA drugs does not influence the stability of the cage-shaped structure; (F) The DLS characterization of the nanoparticles, it can be seen from the figure that the hydrodynamic diameter of the ferritin nanoparticles loaded with one drug is slightly higher than that of ferritin, and the hydrodynamic diameter of the ferritin nanoparticles loaded with two drugs is slightly higher than that of the ferritin nanoparticles loaded with one drug.
FIG. 3 is the drug release of example 3, wherein (A) the drug release of HFtn-DOX and HFtn-UA, (B) the drug release of HFtn-DOX/UA;
FIG. 4 is the cytotoxicity assay and drug synergy analysis in examples 4 and 5; wherein, (A) the free drug and MCF-7 cells are incubated for 24h to ensure the in vitro cell viability; (B) The in vitro cell activity of the drug-loaded nanoparticles and MCF-7 cells after incubation for 24h; (C) Drug Combination Index (CI) of doxorubicin and ursolic acid drug synergy in MCF-7 cells;
FIG. 5 shows the FITC-labeled ferritin uptake by MCF-7 cells as measured by confocal laser and flow cytometry in example 6; wherein, (A) MCF-7 cells were incubated with free FITC and FITC-HFtn for 4h fluorescence images with white lines representing a size of 20 μm; (B) Measuring uptake of free FITC, FITC-HFtn by MCF-7 cells by flow cytometry; (C) mean fluorescence intensity analyzed according to panel B (n = 3).
Detailed Description
In order to make the aforementioned objects, features and advantages of the present invention more comprehensible, embodiments accompanying specific embodiments of the present invention are described in detail below.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, however, the present invention may be practiced otherwise than as specifically described herein, and it will be appreciated by those skilled in the art that the present invention may be practiced without departing from the spirit and scope of the present invention and that the present invention is not limited by the specific embodiments disclosed below.
Furthermore, reference herein to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one implementation of the invention. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments.
In order to improve the therapeutic effect and reduce the generation of drug resistance, most cancer treatments in clinic use anticancer drugs with different mechanisms in combination. The invention provides a preparation method of a ferritin drug-loaded nanoparticle carrying two drugs together, the ferritin nanoparticle effectively delivers the two drugs by targeting on a tumor cell transferrin receptor 1 (TfR 1), compared with delivering a single drug, the method can further enhance the anti-tumor curative effect and reduce the generation of drug resistance, and has good application prospect.
The chemical reagents used in the examples of the present invention are all commercially available analytical reagents unless otherwise specified.
The adriamycin and the ursolic acid used in the embodiment of the invention are purchased from: adriamycin (97% or more) was purchased from Shanghai Aladdin Biotechnology GmbH; ursolic acid (94% or more) was purchased from Sahn chemical technology (Shanghai) Co., ltd; human heavy chain ferritin (HFtn) was purchased from south beijing smithiin biotechnology limited; MCF-7 cells were obtained from the China academy of sciences type culture Collection cell Bank.
Example 1:
preparing the ferritin nanoparticles loaded with the adriamycin and the ursolic acid medicaments together by a temperature method:
dissolving the adriamycin medicine with PBS solution, and dissolving the ursolic acid medicine with ethanol solution.
Doxorubicin and ursolic acid drugs were added to 4ml of a ferritin solution, which was in Tris-HCl (20mm, ph = 8.0). The input molar ratio of the ferritin to the adriamycin to the ursolic acid is 1: 150. 1:450, after incubation at 60 ℃ for 4h, centrifugation at 12000rpm for 10min, the supernatant was separated and dialyzed against PBS for 36h. After the dialysis is finished, centrifuging for 5min under the condition of 5000 Xg, filtering the supernatant by using a filter membrane of 0.45 μm to obtain the ferritin drug-loaded nanoparticles loaded with the adriamycin and the ursolic acid drugs (the method for loading the adriamycin and the ursolic acid drugs independently is the same as the method for loading the adriamycin and the ursolic acid drugs together). The preparation method is shown in figure 1, and the characterization result is shown in figure 2.
Through detection, each ferritin nanoparticle can independently load 100 ursolic acid drugs and 90 adriamycin drugs, and the ferritin nanoparticles jointly loaded with the adriamycin-ursolic acid drugs provided by the invention contain 90 ursolic acid drugs and 18 adriamycin drugs, which are higher than those independently loaded with one drug.
Example 2:
1. the process for preparing the drug-loaded nanoparticles by treating the low-concentration urea comprises the following steps:
dissolving ursolic acid in ethanol solution;
ferritin solution was present in GFC (50 mM Na) 2 HPO 4 ，150mM NaCl, pH 7.0), urea was added to a final concentration of 50mM. Incubating the mixture at 4 deg.C for 2h, adding ethanol-soluble ursolic acid medicine, and slowly stirring at 4 deg.C for 40min at a molar ratio of ferritin to ursolic acid of 1:450, then dialyzing in a PBS solution for 24 hours; after dialysis, the protein liquid in the dialysis bag obtained in the above steps is centrifuged (5000 Xg, 5 min), filtered to obtain the nanoparticles carrying the drug, and the preparation method is shown in figure 1;
the protein nanoparticles loaded with the adriamycin and the ursolic acid are prepared by using the low-concentration urea treatment process, and only the ursolic acid drug is detected, but the adriamycin drug cannot be detected, which indicates that only the ursolic acid drug is loaded. And (4) carrying 65 ursolic acid medicaments per ferritin nanoparticle by low-concentration urea treatment.
2. The process for preparing the drug-loaded nanoparticles by pH method treatment comprises the following steps:
ferritin solution was present in GFC (50 mM Na) 2 HPO 4 150mM NaCl, pH 7.0), adding 1M HCl dropwise to adjust the pH of the solution to 2-3, adding PBS-dissolved adriamycin medicine and ethanol-dissolved ursolic acid medicine, slowly stirring for 40min at 4 ℃ in a chromatography cabinet, then adding 1M NaOH dropwise to readjust the pH of the solution to about 7, and finally dialyzing in the PBS solution for 24h; after dialysis, the protein liquid in the dialysis bag obtained in the above step is centrifuged (5000 Xg, 5 min), and filtered to obtain the drug-loaded nanoparticles. Both drug loads were measured only as single digits by pH.
Example 3:
the in vitro drug release research of the ferritin nanoparticles co-loaded with adriamycin and ursolic acid comprises the following steps:
1ml of ferritin-doxorubicin/ursolic acid solution prepared by the temperature method was placed in a dialysis bag (MWCO 6-8 kDa), placed in PBS buffer at pH =5.0 and pH =7.4, respectively, and dialyzed at 37 ℃ for 60 hours at a stirring speed of 100 rpm. At set time points (0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 60 h), 300 μ L of dialysate was removed and replaced with an equal volume of PBS. The release amount of DOX was measured by fluorescence, and the release amount of UA was measured by high performance liquid chromatography, and the results are shown in FIG. 3. It can be seen from the figure that all three nanoparticles maintain a relatively low release at pH 7.4; the release rates of all three nanoparticles reached higher levels at pH 5.0, indicating that the nanoparticles are unstable at this pH and DOX and UA are released continuously in lysosomes, so HFtn can be an effective drug delivery vehicle.
Example 4:
in vitro cytotoxicity study of ferritin nanoparticles co-loaded with doxorubicin and ursolic acid drugs:
in order to study the in vitro cytotoxicity of the ferritin nanoparticles co-loaded with adriamycin and ursolic acid, MCF-7 cells were seeded in a 96-well plate at a density of 5000 cells per well, after 24 hours of culture at 37 ℃, DOX, UA, HFtn-DOX, HFtn-UA, HFtn-DOX/UA with adriamycin and ursolic acid contents of 0.01-10 μ M/mL and 0.05-50 μ M/mL, respectively, were added to the same well for culture for 24h, pbs was washed twice, MTT was added to the culture medium for incubation for 4 hours, centrifugation was performed, dimethyl sulfoxide (DMSO) was added after carefully removing the supernatant, uv absorption was measured at 490nm, and the survival rates of MCF-7 cells under the action of adriamycin and ursolic acid drugs at different concentrations and drug-loaded nanoparticles are shown in fig. 4, which indicates that the ferritin nanoparticles co-loaded with adriamycin and ursolic acid drugs exhibit strong cytotoxicity, indicating that better therapeutic effects can be achieved by ferritin delivery of two drugs.
Example 5:
research on the synergistic effect of the adriamycin and the ursolic acid medicaments:
to demonstrate the synergistic effect of ferritin loaded DOX and UA, visual expression can be based on drug Combination Index (CI). The CI value is calculated by the following equation:
CI X ＝D a /Dx a +D b /Dx b
wherein D a And D b Is the concentration of drug a and drug b that act together to achieve a particular drug effect. Dx a And Dx b Is the concentration of the single drug counterpart that achieves the same effect. CI values greater than, equal to, and less than 1 reflect antagonism, additivity, and synergy, respectively. Pharmaceutical phaseThe degree of interaction can be obtained by plotting the CI value versus the inhibition rate (Fa value). From FIG. 4 we can see that the CI values for all data points are less than 1, indicating a strong interaction between the two drugs DOX and UA; according to the fitted curve, the Fa value is increased and the CI value is decreased to be stable along with the increase of the concentration of the drug, which shows that when the inhibition rate is increased, the synergistic effect of the drug is stronger but cannot be enhanced infinitely due to certain limitation.
Example 6:
the study on the in vitro cell uptake of the ferritin nanoparticles co-loaded with the adriamycin and the ursolic acid comprises the following steps:
to study the uptake of ferritin co-loaded with both doxorubicin and ursolic acid by cells, MCF-7 cells were plated at 3X 10 per well 4 Inoculating into a 24-pore plate with a glass slide, culturing for 24h, adding 20 microgram/mL FITC-labeled HFtn nanoparticles, incubating for 4h, washing cells for 3 times with PBS, and fixing with 4% paraformaldehyde at room temperature for 30min; and then, the cells are washed twice by PBS, DAPI is added for cell nucleus staining, and the cells are imaged by a laser confocal microscope, so that the result is shown in figure 5, and the FITC-labeled ferritin group shows strong fluorescence, which indicates that ferritin can be taken by the cells to achieve targeting.
The ferritin drug-loaded nanoparticles prepared by the temperature method in example 1 can be used for loading two drugs adriamycin-ursolic acid together. Compared with the pH method in the embodiment 2, the temperature method can greatly reduce the loss of ferritin and improve the loading capacity, and the pH method only has a very small amount of two medicines loaded, basically the proteins are accumulated and precipitated, and subsequent experiments cannot be carried out; compared with the urea treatment with low concentration, the invention not only can load two drugs at the same time, but also can further enhance the amount of the loaded drugs. In summary, the temperature method provided by the present invention: (1) two drugs can be loaded; (2) the loss of protein is reduced; (3) further enhancing the amount of drug loaded.
The invention provides a preparation method and application of a ferritin drug-loaded nanoparticle jointly loaded with two drugs, the nanoparticle effectively delivers the two drugs by targeting on a tumor cell transferrin receptor 1 (TfR 1), compared with the delivery of a single drug, the method can further enhance the anti-tumor curative effect and reduce the generation of drug resistance, and the ferritin drug-loaded nanoparticle loads the two drugs together by ferritin, has simple steps, keeps the original structure of the ferritin complete and has good application prospect.
It should be noted that the above-mentioned embodiments are only for illustrating the technical solutions of the present invention and not for limiting, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, which should be covered by the claims of the present invention.
Claims (5)
1. A preparation method of a ferritin nanoparticle co-loaded with adriamycin and ursolic acid is characterized by comprising the following steps: the ferritin nanoparticles are loaded with hydrophilic adriamycin and hydrophobic ursolic acid drugs together by a temperature method, and comprise,
dissolving the adriamycin medicine with a PBS solution, and dissolving the ursolic acid medicine with an ethanol solution;
after dissolving, respectively putting into a ferritin solution, incubating for 4 to 5 hours at 60 ℃, centrifuging, removing supernate and dialyzing;
centrifuging again after dialysis is finished, and filtering supernate by using a filter membrane to obtain ferritin drug-loaded nanoparticles loaded with adriamycin and ursolic acid drugs;
wherein the ferritin solution is Tris-HCl solution of human heavy chain ferritin with the concentration of 20mM and the pH of 8.0; the molar ratio of the adriamycin to the ferritin is 50-300: 1, the molar ratio of the ursolic acid to the ferritin is 450:1.
2. the method for preparing the ferritin nanoparticles co-loaded with adriamycin and ursolic acid according to claim 1, wherein the method comprises the following steps: the incubation was performed in a thermostated water bath.
3. The method for preparing the nano-particles of ferritin co-loaded with adriamycin and ursolic acid according to claim 1 or 2, which comprises the following steps: and (4) centrifuging after the incubation, wherein the centrifugation speed is 12000rpm, and the centrifugation time is 10 to 15min.
4. The method for preparing the ferritin nanoparticles co-loaded with adriamycin and ursolic acid according to claim 1, wherein the method comprises the following steps: the dialysis is performed in PBS, wherein the dialysis time is 24 to 48 hours, the dialysis temperature is 4 ℃, and the PBS is changed every 6 hours.
5. The method for preparing the ferritin nanoparticles co-loaded with adriamycin and ursolic acid according to claim 1, wherein the method comprises the following steps: and centrifuging after dialysis, wherein the centrifugation condition is 5000 Xg, and the centrifugation time is 5 to 10min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210273421.6A CN114668771B (en) | 2022-03-18 | 2022-03-18 | Preparation method and application of ferritin nanoparticles loaded with adriamycin and ursolic acid together |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210273421.6A CN114668771B (en) | 2022-03-18 | 2022-03-18 | Preparation method and application of ferritin nanoparticles loaded with adriamycin and ursolic acid together |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114668771A CN114668771A (en) | 2022-06-28 |
| CN114668771B true CN114668771B (en) | 2022-12-06 |
Family
ID=82074046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210273421.6A Active CN114668771B (en) | 2022-03-18 | 2022-03-18 | Preparation method and application of ferritin nanoparticles loaded with adriamycin and ursolic acid together |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114668771B (en) |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102133191A (en) * | 2011-03-16 | 2011-07-27 | 中国药科大学 | Transferrin and albumin composite nano particle and preparation method and application thereof |
| CN102133190A (en) * | 2011-03-16 | 2011-07-27 | 中国药科大学 | Transferrin nanoparticles and preparation method and application thereof |
| CN104013599A (en) * | 2014-05-28 | 2014-09-03 | 中国科学院生物物理研究所 | Drug carrier capable of realizing drug delivery specifically targeting tumor and application thereof |
| CN109045303A (en) * | 2018-08-14 | 2018-12-21 | 江苏省中医药研究院 | A kind of Chinese medicine-magnetic nano-cluster chemo-immunity drug delivery system and preparation method thereof |
| CN109486827A (en) * | 2018-12-04 | 2019-03-19 | 南京林业大学 | A kind of apoferritin nanocages and preparation method thereof of tumor-homing cell-penetrating peptide tLyP-1 modification |
| CN109553684A (en) * | 2017-09-25 | 2019-04-02 | 中国科学院过程工程研究所 | A kind of nano-carrier albumen and its preparation method and application |
| CN110721316A (en) * | 2019-10-08 | 2020-01-24 | 浙江大学 | Triphenylphosphine-adriamycin-iron chelate drug delivery system and preparation method and application thereof |
| CN111939138A (en) * | 2019-05-17 | 2020-11-17 | 南京林业大学 | Method for preparing taxol nano-drug by taking apoferritin as carrier and recovering taxol |
| CN111939273A (en) * | 2019-05-17 | 2020-11-17 | 南京林业大学 | Preparation method of tumor nanoprobe with ferritin as carrier |
| CN112121029A (en) * | 2020-09-08 | 2020-12-25 | 中国药科大学 | Bionic dopamine polymerization drug-loaded nano delivery system and preparation method thereof |
| CN112426534A (en) * | 2020-12-07 | 2021-03-02 | 南京林业大学 | Ferritin nanoparticle with C-terminal modified tumor penetrating peptide RGERPPR, and preparation method and application thereof |
| CN113105556A (en) * | 2021-02-20 | 2021-07-13 | 南京林业大学 | Ferritin nanoparticle for modifying ERK polypeptide inhibitor and preparation method and application thereof |
-
2022
- 2022-03-18 CN CN202210273421.6A patent/CN114668771B/en active Active
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102133191A (en) * | 2011-03-16 | 2011-07-27 | 中国药科大学 | Transferrin and albumin composite nano particle and preparation method and application thereof |
| CN102133190A (en) * | 2011-03-16 | 2011-07-27 | 中国药科大学 | Transferrin nanoparticles and preparation method and application thereof |
| CN104013599A (en) * | 2014-05-28 | 2014-09-03 | 中国科学院生物物理研究所 | Drug carrier capable of realizing drug delivery specifically targeting tumor and application thereof |
| CN109553684A (en) * | 2017-09-25 | 2019-04-02 | 中国科学院过程工程研究所 | A kind of nano-carrier albumen and its preparation method and application |
| CN109045303A (en) * | 2018-08-14 | 2018-12-21 | 江苏省中医药研究院 | A kind of Chinese medicine-magnetic nano-cluster chemo-immunity drug delivery system and preparation method thereof |
| CN109486827A (en) * | 2018-12-04 | 2019-03-19 | 南京林业大学 | A kind of apoferritin nanocages and preparation method thereof of tumor-homing cell-penetrating peptide tLyP-1 modification |
| CN111939138A (en) * | 2019-05-17 | 2020-11-17 | 南京林业大学 | Method for preparing taxol nano-drug by taking apoferritin as carrier and recovering taxol |
| CN111939273A (en) * | 2019-05-17 | 2020-11-17 | 南京林业大学 | Preparation method of tumor nanoprobe with ferritin as carrier |
| CN110721316A (en) * | 2019-10-08 | 2020-01-24 | 浙江大学 | Triphenylphosphine-adriamycin-iron chelate drug delivery system and preparation method and application thereof |
| CN112121029A (en) * | 2020-09-08 | 2020-12-25 | 中国药科大学 | Bionic dopamine polymerization drug-loaded nano delivery system and preparation method thereof |
| CN112426534A (en) * | 2020-12-07 | 2021-03-02 | 南京林业大学 | Ferritin nanoparticle with C-terminal modified tumor penetrating peptide RGERPPR, and preparation method and application thereof |
| CN113105556A (en) * | 2021-02-20 | 2021-07-13 | 南京林业大学 | Ferritin nanoparticle for modifying ERK polypeptide inhibitor and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114668771A (en) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gong et al. | A review on plant polysaccharide based on drug delivery system for construction and application, with emphasis on traditional Chinese medicine polysaccharide | |
| Lin et al. | Ligand-modified erythrocyte membrane-cloaked metal–organic framework nanoparticles for targeted antitumor therapy | |
| CN107865972B (en) | Preparation method and application of multifunctional membrane-controlled targeting nano-carrier with tracing and targeting drug delivery functions | |
| CN105727307B (en) | Lipoic acid modified nano-polypeptide carrier and preparation method and application thereof | |
| Chen et al. | Orally deliverable sequence-targeted astaxanthin nanoparticles for colitis alleviation | |
| CN112933052A (en) | Nano drug delivery system for improving tumor hypoxia microenvironment and enhancing immunotherapy | |
| CN108339124B (en) | Preparation method and application of two-stage brain-targeted polymer micelle drug delivery system | |
| CN107049955A (en) | A kind of multistage targeting hyaluronan nanoparticle for carrying methotrexate (MTX) and preparation method thereof | |
| Liu et al. | E-Selectin-binding peptide–modified bovine serum albumin nanoparticles for the treatment of acute lung injury | |
| CN112089838B (en) | Black phosphorus nanogel medicine for tumor microenvironment response and preparation method and application thereof | |
| CN112386585B (en) | Self-assembled nano-drug and preparation method and application thereof | |
| CN114668771B (en) | Preparation method and application of ferritin nanoparticles loaded with adriamycin and ursolic acid together | |
| CN110897998B (en) | Genetic engineering polypeptide nano hydrogel simultaneously loaded with hydrophobic drug and hydrophilic drug and preparation method thereof | |
| CN108339125A (en) | It is a kind of efficiently, targeted medicament carrying nano micella and preparation method and application | |
| WO2023193389A1 (en) | Resveratrol-lecithin nanoparticle, method for preparing same, and use thereof | |
| CN106619569B (en) | The cancer target nanoparticle and preparation method of chemotherapeutics and nucleic acid are carried altogether | |
| CN114533698B (en) | Preparation method of ferritin drug-loaded nanoparticles modified with D-type tumor penetrating peptide | |
| CN107823652B (en) | Long-circulation self-assembly composite nano preparation, preparation method and application thereof | |
| Song et al. | Preparation and evaluation of insulin-loaded nanoparticles based on hydroxypropyl-β-cyclodextrin modified carboxymethyl chitosan for oral delivery | |
| CN116077460A (en) | Ganoderan nanoparticle loaded with chemotherapeutic drugs | |
| CN111388449B (en) | Polyornithine/carboxymethyl lentinan layer-by-layer self-assembly drug carrier and preparation method thereof | |
| CN109395086B (en) | Graphene oxide-based composite nano-drug carrier and preparation method thereof | |
| CN107812189B (en) | Hypocrellin nano preparation for actively targeting specific tumor cells and preparation method and application thereof | |
| CN115192546B (en) | Multifunctional nanoparticle for targeting liver cancer stem cells and preparation method thereof | |
| CN110151728A (en) | A kind of double erythrocyte membrane composite nano-granules for carrying the pure and mild IR780 of Taxotere |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |